Results of Twitter poll on 2Q18 ABBV/ENTA HCV sales: a) <$1.0B: 18% b) ≥$1.0B but <$1.1B: 20% c) ≥$1.1B but <$1.2B: 24% d) ≥$1.2B: 38% All told, these responses seem unduly bullish, IMO. (ABBV’s 1Q18 HCV sales were $919M; GILD’s 2Q18 HCV sales were $1.00B.) Thanks to all of the participants for participating.